Collectively, these findings underscore the emerging role of SGLT2 inhibitors as a promising adjunctive strategy in the management of AS, capable not only of improving post-procedural outcomes but also of intervening in the cardiometabolic remodeling process that underlies disease progression and long-term morbidity. This evidence concerns the gene SLC5A2 and aortic stenosis.